Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > PHIZER just bought Trillium ---for--

<< Previous

Bullboard Posts

Next >>

Comment by HomerAndCompanyon Aug 24, 2021 7:30am

451 Views

Post# 33753635

RE:RE:RE:PHIZER just bought Trillium ---for--

My math says a 200% premium on 20.5 cents is the low 60 cent range. But maybe we could see a 200% premium on a future higher SP?

A $5 SP for example would give TLT a market cap of just over $1 billion, and a 200% premium on that would be just over $3 billion & $15/share.

Pandora wrote: And what does a 200% premium to 20.5 cents give us??

HomerAndCompany wrote: $18.50/share, closing price was $6.09, so >200% premium.

Aug 23 (Reuters) - Trillium Therapeutics Inc:

* PFIZER TO ACQUIRE TRILLIUM THERAPEUTICS INC.

* TRILLIUM THERAPEUTICS INC - DEAL FOR IMPLIED EQUITY VALUE OF $2.26 BILLION

* TRILLIUM THERAPEUTICS INC - DEAL FOR $18.50 PER SHARE, IN CASH

* TRILLIUM THERAPEUTICS INC - PROPOSED DEAL OF TRILLIUM IS TO BE COMPLETED BY WAY OF A STATUTORY PLAN OF ARRANGEMENT UNDER BUSINESS CORPORATIONS ACT

* TRILLIUM THERAPEUTICS INC - COMPLETION OF ACQUISITION IS ALSO SUBJECT TO COURT AND REGULATORY APPROVAL, CERTAIN OTHER CONDITIONS Source text for Eikon: Further company coverage: